Abstract
Tumor suppressor p53 maintains genome stability by regulating diverse cellular functions including cell cycle arrest, apoptosis, senescence and metabolic homeostasis. Mutations in the p53 gene occur in almost all human cancers with a frequency of up to 80%. However, it is only 20% in breast cancers, 18% in endometrial cancers and 1.5% in cervical cancers. Estrogen receptor alpha (ERα) plays a pivotal role in hormone-dependent cancer development and the status of ERα is used for designing treatment strategy and for prognosis. A closer look at the cross-talk between p53 and ERα has revealed that their activities are mutually regulated. This review will summarize the current body of knowledge on p53, ERα and ERβ in cancer. Clinical correlations between estrogen receptors and p53 status have also been reported. Thus, this review will discuss the relationship between p53 and ERs at both the molecular and clinical levels.
Keywords: Estrogen receptor, hormone-dependent cancer, p53, transcription factors.
Current Molecular Medicine
Title:The p53-Estrogen Receptor Loop in Cancer
Volume: 13 Issue: 8
Author(s): C. Berger, Y. Qian and X. Chen
Affiliation:
Keywords: Estrogen receptor, hormone-dependent cancer, p53, transcription factors.
Abstract: Tumor suppressor p53 maintains genome stability by regulating diverse cellular functions including cell cycle arrest, apoptosis, senescence and metabolic homeostasis. Mutations in the p53 gene occur in almost all human cancers with a frequency of up to 80%. However, it is only 20% in breast cancers, 18% in endometrial cancers and 1.5% in cervical cancers. Estrogen receptor alpha (ERα) plays a pivotal role in hormone-dependent cancer development and the status of ERα is used for designing treatment strategy and for prognosis. A closer look at the cross-talk between p53 and ERα has revealed that their activities are mutually regulated. This review will summarize the current body of knowledge on p53, ERα and ERβ in cancer. Clinical correlations between estrogen receptors and p53 status have also been reported. Thus, this review will discuss the relationship between p53 and ERs at both the molecular and clinical levels.
Export Options
About this article
Cite this article as:
Berger C., Qian Y. and Chen X., The p53-Estrogen Receptor Loop in Cancer, Current Molecular Medicine 2013; 13 (8) . https://dx.doi.org/10.2174/15665240113139990065
DOI https://dx.doi.org/10.2174/15665240113139990065 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides
Current HIV Research Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Dantrolene Potentiates the Antineoplastic Effect of Sorafenib in Hepatocellular Carcinoma via Targeting Ca<sup>+2</sup>/PI3K Signaling Pathway
Current Molecular Pharmacology The Mechanism of Adjuvanticity of Aluminium-Containing Formulas
Current Pharmaceutical Design Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs
Anti-Cancer Agents in Medicinal Chemistry Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Withdrawal Notice: Prognosis And Prediction Of Breast Cancer (Bc) Using Growing Mlt (Machine Learning Techniques)
Recent Advances in Computer Science and Communications CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets Current Targets for Anticancer Drug Discovery
Current Drug Targets Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair
Current Stem Cell Research & Therapy Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Inhibition of Growth of Esophageal Cancer by Alantolactone via Wnt/β- Catenin Signaling
Anti-Cancer Agents in Medicinal Chemistry